{"id":"methylphenidate-extended-release-capsules","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"10-20","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking dopamine and norepinephrine transporters, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced neurotransmitter activity improves attention, focus, and impulse control. The extended-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing.","oneSentence":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:46.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT06577779","phase":"PHASE4","title":"An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-01-29","conditions":"Attention-deficit/Hyperactivity Disorder","enrollment":30},{"nctId":"NCT04987762","phase":"PHASE4","title":"Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2021-08-03","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":103},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT03811847","phase":"PHASE4","title":"A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-01","conditions":"Alzheimer Dementia","enrollment":11},{"nctId":"NCT01239030","phase":"PHASE3","title":"Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2010-11","conditions":"Attention Deficit Hyperactivity Disorder, ADHD","enrollment":230},{"nctId":"NCT02683265","phase":"PHASE4","title":"A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-04-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":158},{"nctId":"NCT01269463","phase":"PHASE3","title":"Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2011-01-19","conditions":"Attention Deficit Hyperactivity Disorder, ADHD","enrollment":26},{"nctId":"NCT02470234","phase":"PHASE4","title":"Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":10},{"nctId":"NCT02520388","phase":"PHASE3","title":"A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2015-08","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":163},{"nctId":"NCT04138498","phase":"PHASE1, PHASE2","title":"CTx-1301 Comparative Bioavailability Study","status":"COMPLETED","sponsor":"Cingulate Therapeutics","startDate":"2019-12-06","conditions":"ADHD","enrollment":45},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT02677519","phase":"PHASE4","title":"A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD","status":"UNKNOWN","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2016-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":120},{"nctId":"NCT02168127","phase":"PHASE3","title":"Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD","status":"COMPLETED","sponsor":"Rhodes Pharmaceuticals, L.P.","startDate":"2014-05","conditions":"ADHD","enrollment":360},{"nctId":"NCT01338818","phase":"PHASE3","title":"Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":299},{"nctId":"NCT01259492","phase":"PHASE3","title":"Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":"Attention Deficit/Hyperactivity Disorder","enrollment":725},{"nctId":"NCT00922636","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":340},{"nctId":"NCT01348607","phase":"PHASE2","title":"Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2010-07","conditions":"Central Nervous System Tumor, Pediatric, Fatigue, Specific Disorders of Sleep","enrollment":1},{"nctId":"NCT00178503","phase":"PHASE2, PHASE3","title":"Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-09","conditions":"Autism, Attention Deficit Disorder With Hyperactivity","enrollment":24},{"nctId":"NCT00564954","phase":"PHASE4","title":"A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":86},{"nctId":"NCT00776009","phase":"PHASE4","title":"Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":165},{"nctId":"NCT00428792","phase":"PHASE3","title":"Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":150},{"nctId":"NCT00381758","phase":"PHASE4","title":"The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":184},{"nctId":"NCT00619840","phase":"PHASE3","title":"Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD","status":"COMPLETED","sponsor":"Medice Arzneimittel Pütter GmbH & Co KG","startDate":"2004-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":363}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABNORMAL BEHAVIOUR"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"FEELING ABNORMAL"},{"count":1,"reaction":"HYPERSEXUALITY"},{"count":1,"reaction":"PRODUCT SUBSTITUTION ISSUE"}],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biphentin"],"phase":"marketed","status":"active","brandName":"Methylphenidate Extended Release Capsules","genericName":"Methylphenidate Extended Release Capsules","companyName":"UCB Pharma","companyId":"ucb-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults, Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}